Emily Heffernan, director of new process technologies at Arcadis, explains what it takes to design a facility that can produce both lentiviral vectors and mRNA-LNPs, and how in vivo platforms change QC release testing.
Emily Heffernan
Advertisement
Emily Heffernan, US director new process technologies at Arcadis is a process subject matter expert, specializing in biological process and facility design. With more than 20 years’ experience, her expertise spans across multiple therapeutic areas including monoclonal antibodies, vaccines, cell and gene therapies, and RNA therapeutics.
Articles by Emily Heffernan
Emily Heffernan of Arcadis explains how facility scale, equipment, containment, and quality testing differ across ex vivo cell therapy, viral vector, and mRNA-LNP manufacturing.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
2
Lonza to Acquire Merck KGaA’s US CDMO Business, Adding ADC, Viral Vector, and LNP Capacity
3
Policy Leaders Urge Treasury to Narrow Biotech Outbound Investment Rule
4
FDA Finalizes Potency Assurance Guidance for Cell and Gene Therapies
5